TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11970761

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox 9 microg/kg/day or 18 microg/kg/day, administered intravenously over 15-60 minutes for 5 consecutive days, cycles every 21 days for a total of 8 cycles over 6 months.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (responders),
Number of subjects: 71
Study: 10323055

Group type: EXPERIMENTAL
Intervention: NPH Insulin (20 to 40 units at bedtime)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metformin (up to 3 grams) combined with Sulphonylureas
Number of subjects: 36
Study: 8129407

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil solution
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 2490930

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin application (experimental side)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control sides (no glycyrrhizin application)
Number of subjects: 21
Study: 31069904

Group type: EXPERIMENTAL
Intervention: Structured Interdisciplinary Bedside Rounding (SIBR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional rounds (Control)
Number of subjects: 78
Study: 30915564

Group type: EXPERIMENTAL
Intervention: DTA model based on CT findings alone
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: DTA model based on imaging and clinical findings
Number of subjects: 290
Study: 28646934

Group type: EXPERIMENTAL
Intervention: 2-minute delay of peri-prostatic lidocaine injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10-minute delay of peri-prostatic lidocaine injection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subset analysis of biopsies 1-3, 4-6, 7-9 and 10-12 with 2-minute delay
Number of subjects: 80
Study: 26051236

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 75
Study: 23816438

Group type: EXPERIMENTAL
Intervention: High vegetable content meal
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: High-meat meal
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control meal (150 g cooked rice, sautéed beef menu containing 40 g raw beef, and 240 g vegetable)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Low-ED meals
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Increased rice content
Number of subjects: 276
Study: 20663999

Group type: EXPERIMENTAL
Intervention: Aspirin plus famotidine 20 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin plus lansoprazole 15 mg once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 15
Study: 19858398

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU)
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Irinotecan/FU (IrFU)
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/FU (OxFU)
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Irinotecan alone
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: UGT1A1*28
Number of subjects: 1036
Study: 16431254

Group type: EXPERIMENTAL
Intervention: 100 mg of topical 1% testosterone gel (Testim) applied daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15203583

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene and Atorvastatin (combined treatment)
Number of subjects: 0
Study: 11531673

Group type: EXPERIMENTAL
Intervention: Lockit epidural catheter clamp
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard epidural dressing
Number of subjects: 102
Study: 9415763

Group type: EXPERIMENTAL
Intervention: Copalite (Harry J. Bosworth Co.) with or without Vitrebond (3M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgambond Plus (Parkell)
Number of subjects: 0
Study: 8507446

Group type: EXPERIMENTAL
Intervention: Octreotide infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline infusion alone
Number of subjects: 28
Study: 3690524

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) 300 mg X 3 daily for 4 weeks and 500 mg X 2 weekly thereafter
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intramuscular (im) medroxyprogesterone acetate (MPA) 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter
Number of subjects: 123

Group type: COMPARATOR
Intervention: Both oral and im MPA
Number of subjects: 123
Study: 29246264

Group type: EXPERIMENTAL
Intervention: MAP index threshold ≥ 0.5
Number of subjects: 264
Study: 26954408

Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg/d and Bupropion 360 mg/d
Number of subjects: 8910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8910
Study: 24232442

Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: citalopram
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 22949154

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg per day
Number of subjects: 502

Group type: COMPARATOR
Intervention: Imatinib 400 mg per day
Number of subjects: 502
Study: 20738171

Group type: COMPARATOR
Intervention: 37% phosphoric acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + 2% CHX
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + KTP laser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (CPB)
Number of subjects: 60
Study: 18422674

Group type: EXPERIMENTAL
Intervention: Echocardiographic diastolic dysfunction grade
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tissue Doppler velocities Em
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tissue Doppler velocities Am
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flow propagation velocity
Number of subjects: 52
Study: 15731976

Group type: EXPERIMENTAL
Intervention: Standardized basic psychological support
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Optional psychological support or intensive assistance
Number of subjects: 152
Study: 14572180

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent individuals with PTSD
Number of subjects: 558

Group type: COMPARATOR
Intervention: Cocaine-dependent individuals without PTSD
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent individuals
Number of subjects: 558
Study: 11193558

Group type: EXPERIMENTAL
Intervention: Ro64‐0796 75 mg once daily for six weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 8880944

Group type: EXPERIMENTAL
Intervention: Experimental cigarettes with varying nicotine/tar yields (0.08/8.5, 0.17/9.1, 0.37/9.8, 0.48/9.8, 0.74/10.4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Commercial 'light' (CL) cigarette (0.71/8.6)
Number of subjects: 32
Study: 1892482

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) and newly diagnosed NIDDM
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Previously diagnosed NIDDM
Number of subjects: 1431
Study: 6303794

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Miconazole or Ketoconazole
Number of subjects: 88
Study: 31804965

Group type: EXPERIMENTAL
Intervention: Late-night salivary cortisol (LNSC)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mean urinary free cortisol (mUFC)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both mLNSC and mUFC controlled
Number of subjects: 137
Study: 30315333

Group type: EXPERIMENTAL
Intervention: Filmed social contact
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Internet-based self-study
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study: 26171969

Group type: EXPERIMENTAL
Intervention: Realignment therapy using a valgus unloader knee brace plus bilateral neutral foot orthoses and motion control shoes for 12 weeks
Number of subjects: 48
Study: 25504030

Group type: EXPERIMENTAL
Intervention: High dietary carbohydrate (CHO) group
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Weight-regain phase
Number of subjects: 730
Study: 23108692

Group type: EXPERIMENTAL
Intervention: Latrepirdine (20 mg) administered orally 3 times daily for 26 weeks
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo administered orally 3 times daily for 26 weeks
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Latrepirdine
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 22142350

Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium
Number of subjects: 407

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 407

Group type: COMPARATOR
Intervention: Naproxen Sodium
Number of subjects: 407
Study: 19410462

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy with tamoxifen or anastrozole
Number of subjects: 43
Study: 17704975

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 15761167

Group type: EXPERIMENTAL
Intervention: Self-refilling bowl
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal bowl
Number of subjects: 54
Study: 11884295

Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/d, riboflavin 5 mg/d, B12 0.4 mg/d
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Vitamin B6 50 mg/d (with folic acid treatment)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 10453925

Group type: EXPERIMENTAL
Intervention: Low-intensity general conditioning programme (12 weeks, exercise intensity < 60% heart rate reserve, 60 min, 3 times a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups underwent anthropometric measures and maximal cycling test for VO2max
Number of subjects: 20
Study: 7770930

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b (IFNa) 3 million units three times weekly for 6 months (group A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 14
Study: 2236444

Group type: EXPERIMENTAL
Intervention: Contingent reward conditions (easy, difficult, very difficult)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncontingent reward condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficult condition
Number of subjects: 0
Study: 348225

Group type: EXPERIMENTAL
Intervention: Salbutamol by pressure-packed aerosol 200 microgram
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Salbutamol by intermittent positive pressure ventilation (IPPV) 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Salbutamol by intermittent positive pressure ventilation (IPPV) 10 mg
Number of subjects: 60
Study: 31606289

Group type: EXPERIMENTAL
Intervention: Volumetric measurements using 3D MRI imaging software
Number of subjects: 24

Group type: COMPARATOR
Intervention: Kerboul et al method
Number of subjects: 24

Group type: COMPARATOR
Intervention: Koo and Kim method
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cherian et al method
Number of subjects: 24
Study: 31366975

Group type: EXPERIMENTAL
Intervention: Defibrotide infusion (6.25 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 28264739

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 25589224

Group type: EXPERIMENTAL
Intervention: 3D-CRT 70 Gy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: 3D-CRT 74 Gy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: IMRT 78 Gy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: IMRT/SIB 82 Gy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: 3D-CRT
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 553
Study: 23996515

Group type: EXPERIMENTAL
Intervention: Prematurely born children (Cluster A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prematurely born children (overall group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prematurely born children (Cluster B)
Number of subjects: 46
Study: 22129109

Group type: EXPERIMENTAL
Intervention: LPC vaccination alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: PCV2 inoculation/LPC vaccination
Number of subjects: 18
Study: 18620831

Group type: EXPERIMENTAL
Intervention: Skin testing with non-ionic monomer RCM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Controlled challenge tests with alternative non-ionic monomer RCM
Number of subjects: 32
Study: 17385591

Group type: EXPERIMENTAL
Intervention: Hydrosorb comfort hydrogel dressing
Number of subjects: 81
Study: 15469615

Group type: EXPERIMENTAL
Intervention: Dedicated machines (D) for HCV infected individuals
Number of subjects: 593

Group type: COMPARATOR
Intervention: Non-dedicated HD machines (ND)
Number of subjects: 593
Study: 11509263

Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 41
Study: 9658386

Group type: EXPERIMENTAL
Intervention: Low dose sodium valproate for 3 months
Number of subjects: 27
Study: 7805431

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid (500 mg three times daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 251

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 251
Study: 2780100

Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone (group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone (group II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone in peritonitis (group III)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone in peritonitis (group IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone
Number of subjects: 50
Study: 53081

Group type: EXPERIMENTAL
Intervention: 67Gallium-citrate
Number of subjects: 28

Group type: COMPARATOR
Intervention: 111Indium-bleomycin
Number of subjects: 28
Study: 31196599

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28619649

Group type: EXPERIMENTAL
Intervention: Integrated pest management
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Air purifiers
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 24890861

Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delayed placement (De)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Late placement (La)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Implants with dehiscence defect
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Implants with intrabony defect
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Implants without defect
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison of bBL between implants with and without defect
Number of subjects: 63

Group type: COMPARATOR
Intervention: Overall comparison of BIC among groups
Number of subjects: 63
Study: 22359240

Group type: EXPERIMENTAL
Intervention: Financial interventions covering part of women's costs for prenatal and postnatal care
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Training of midwives in clinical skills
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Health education training for midwives and village doctors
Number of subjects: 3673
Study: 21816309

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Defibrillator-only
Number of subjects: 1820
Study: 19781431

Group type: EXPERIMENTAL
Intervention: L‐N(G)‐monomethyl‐arginine
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Norepinephrine dose
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure at 2 hours
Number of subjects: 396
Study: 16719651

Group type: EXPERIMENTAL
Intervention: SSL theory (strategy selection learning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best-performing strategy from participants' repertoires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSL model
Number of subjects: 0
Study: 12969156

Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low sodium diet (40 mmol/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sodium loading (after high salt intake)
Number of subjects: 27
Study: 10713296

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharin (23.7 mg)
Number of subjects: 0
Study: 9377617

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d for 7 days followed by 0.8 mg/d for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1384146

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 0
Study: 3965001

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (T)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Tetanus-diphtheria toxoid (Td)
Number of subjects: 193
Study: 31402223

Group type: EXPERIMENTAL
Intervention: 20 mL 0.5% plain bupivacaine (100 mg) plus 20 mL liposomal bupivacaine (266 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 40 mL 0.25% plain bupivacaine (100 mg)
Number of subjects: 74
Study: 30515484

Group type: EXPERIMENTAL
Intervention: BB group (anorganic bovine bone and porcine collagen membranes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CJ group (synthetic resorbable bone graft substitute made of pure β‐tricalcium phosphate and porcine pericardium collagen membranes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BB group
Number of subjects: 50

Group type: COMPARATOR
Intervention: CJ group
Number of subjects: 50
Study: 26655594

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 61
Study: 24799482

Group type: EXPERIMENTAL
Intervention: PET-negative residues after chemotherapy (548 patients)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: PET-positive patients receiving additional radiotherapy (191 patients)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: PET-positive patients with relative reduction of less than 40% (54 patients)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: PET-positive patients with larger reduction
Number of subjects: 739
Study: 22443921

Group type: EXPERIMENTAL
Intervention: Manual compression with hemostatic patch
Number of subjects: 89

Group type: COMPARATOR
Intervention: Manual compression alone (control group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (manual compression with and without hemostatic patch)
Number of subjects: 89
Study: 20185734

Group type: EXPERIMENTAL
Intervention: Oral insulin (OI) - 300 units combined with 400 mg of delivery agent orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subcutaneous regular human insulin (RHI) - 15 units
Number of subjects: 10
Study: 18602250

Group type: EXPERIMENTAL
Intervention: Daily supplements containing 60 mg of iron and 250 microg of folic acid plus 25 mg of zinc
Number of subjects: 242

Group type: COMPARATOR
Intervention: Daily supplements containing 60 mg of iron and 250 microg of folic acid
Number of subjects: 242
Study: 11465711

Group type: EXPERIMENTAL
Intervention: Active treatment (specific treatments not detailed)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 10036659

Group type: EXPERIMENTAL
Intervention: Flow cytometrically diploid tumours
Number of subjects: 116

Group type: COMPARATOR
Intervention: Aneuploid tumours
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Aneuploid T1 tumours
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Diploid T1 tumours
Number of subjects: 116
Study: 8158065

Group type: EXPERIMENTAL
Intervention: Saphenous patch (Group B)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Prosthetic Gore-Tex patch (Group C)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Direct closure (Group A)
Number of subjects: 188
Study: 2895124

Group type: EXPERIMENTAL
Intervention: Hexetidine containing toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme containing toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual antibacterial activity with hexetidine toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Residual antibacterial activity with chlorhexidine gel
Number of subjects: 0
Study: 30179280

Group type: EXPERIMENTAL
Intervention: Cancer-PEPSONE programme (CPP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Support as usual (Control)
Number of subjects: 35
Study: 28082387

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) at 90% to 95% of maximal heart rate
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT) at 60% to 70% of maximal heart rate
Number of subjects: 261

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Regular Exercise Recommendation (RRE)
Number of subjects: 261
Study: 26073754

Group type: EXPERIMENTAL
Intervention: HDM extract (active) administered orally twice daily for 12 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo solution administered orally twice daily for 12 months
Number of subjects: 111
Study: 24016147

Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA) in patients with paroxysmal AF (PAF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Catheter ablation (CA) in patients with paroxysmal AF (PAF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA) in patients with persistent AF (PersAF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Catheter ablation (CA) in patients with persistent AF (PersAF)
Number of subjects: 64